Abstract. Tumor necrosis factor-alpha (TNF-α) has been used as an effective treatment for Hepatocellular Carcinoma, however, inducing tumor cell apoptosis by TNF-α alone is still unsatisfactory. RhoA is highly expressed in hepatocarcinoma cells and can be activated by TNF-α. The activation of RhoA directly leads to a poor prognosis of HCC. Therefore, we propose to investigate the therapeutic effect of TNF-α together with RhoA siRNA. RhoA inhibition was accomplished by constructing a recombinant adenovirus that can efficiently express RhoA siRNA in HepG2 cells. The recombinant adenovirus AdshRNA-RhoA and AdU6-control were generated by adenovirus-mediated siRNA expression system. The inhibition effects were detected by RT-PCR in addition to immunoblot to quantify the decreased levels of RhoA expression, and the therapeutic effect for HCC was demonstrated by the proliferation and apoptosis ratios of HepG2 cells. The inhibition effects of RhoA by AdshRNA-RhoA were significant at both mRNA and protein levels: the transcription of RhoA mRNA decreased by 74.46%, and the expression of protein decreased by 76.48%. The proliferation rate of HepG2 cells detected by MTT showed that a treatment of AdshRNA-RhoA and TNF-α together could strengthen the suppression ability of TNF-α to HepG2 cells, resulting in approximately 14.2% more than those treated with only TNF-α. FCA and TUNEL assays results revealed that the combined treatment can induce apoptosis in approximately 52.14%-65% of the HepG2 cells, whereas this ratio in the TNF-α-alone group was only 21.91%-32%. Our results showed that AdshRNA-RhoA can efficiently enhance the TNF-α-induced apoptosis of hepatocarcinoma cells. This method might be a useful therapeutic route in HCC and other tumors.
Hepatocellular carcinoma (HCC) is one of the deadliest human malignancies, accompanied with a very poor prognosis. TNF-α is a pleiotropic proinflammatory cytokine that is primarily produced by macrophages. The main functions of TNF-α include inducing tumor cell apoptosis, enhancing immun--ocyte differentiation, and increasing the permeability of vascular endothelial cells to target tumor neovessels [1] [2] [3] . Moreover, TNF-α has also been reported to enhance the therapeutic effects of antitumor drugs. For example, W. Cao, et al. [4] demonstrated that TNF-α promoted doxorubicin-induced cell death and anti-cancer effects via the downregulation of p21 in p53-deficient tumor cells. In addition, the delivery of low TNF-α doses to tumor vasculature can increase the efficacy of chemotherapeutic drugs, such as doxorubicin, melphalan, cisplatin, paclitaxel, and gemcitabine, without an increase in drug cytotoxicity [5] . However, the application of TNF-α has certain limitations, including its toxicity [6] and unsatisfactory effects on tumor cell apoptosis [7] , which is correlated to the geranylgeranylation of RhoA [8] .
RhoA belongs to the Rho family of GTPases, and high RhoA protein levels and increased activity have been reported in HCC patients [9] . Activating the RhoA/Rho pathway increases tumor cell migratory properties, such as invadopodia, amoeboid migration, and plasticity abilities [10] . Additionally, the expression level of RhoA is directly correlated to the clinicopathologic outcome, as the overexpression of RhoA has been shown to be directly correlated to a poor prognosis of HCC [11] . Furthermore, X.L. Deng, et al. [12] reported that RhoA activation and expression could be induced by TNF-α in mouse cerebral microvascular endothelial cells, and p115RhoGEF may play a role in this process. Thus, this suggests that RhoA activation may be a mechanism of TNF-α-induced endothelial cell barrier function. The regulatory effects of TNF-α are modulated at very sensitive levels; for instance, picomolar concentrations of TNF-α stimulated the rapid translocation of RhoA to the plasma membrane, which in turn enhanced monocyte chemotaxis, adhesion, and transmigration activities [13] . Therefore, we presumed that the inhibition of RhoA may be a useful strategy for improving the therapeutic effect of TNF-α on HCC.
In this study, the synergetic effect of TNF-α and adenovirus-mediated RhoA siRNA (AdshRNARhoA) on promoting the apoptosis of hepatocarcinoma cells was investigated. The results demonstrated that the expression level of RhoA in hepatocarcinoma cells was significantly inhibited by AdshRNA-RhoA, and the apoptosis rate of cells that had been treated with AdshRNA-RhoA and TNF-α together was higher than that of cells that had only been treated with TNF-α. Our results indicate that RhoA siRNA combined with TNF-α is a potential therapeutic approach for HCC.
Material and methods

siRNAs, plasmids, strains and cell lines
Three pairs of oligonucleotides targeting three different regions of RhoA (GenBank ID: 387) were designed according to the guidelines proposed by T. Tuschl [14] . siRNA-1 (position 430-448): sense: 5'-TCGAGGGCAGAGATATGGCAAACAGAGTACTGTGTTTGCCTATCTCTGCCTTTTT-3'; antisense:5'-CTAGAAAAAGGCAGAGATATGGCAAACACAGTACTCTGTTTGCCTATCTCTG CCC-3'; siRNA-2 (position 226-246): sense:5'-TCGAGGACACCGATGTTATATTGATGGTACTG CATCAATATAACATCGGTGTCTTTTT-3';antisense: 5'-CTAGAAAAAGACACCGATGTTATA TTGATGCAGTACTCCATCAATATAACATCGGTGTCC-3'. siRNA-3 (position 123-144): sense:5'-TCGAGCTATGTGGCGGATATCGAGGTGAGTACTGACCTCGATATCCGCCACATAGTTTTT-3'; antisense:5'-CTAGAAAAACTATGTGGCGGATATCGAGGTCAGTACTCACCTCGATATCC GCCACATAGC-3'. The underlined sequences are Xba I and Xho I digestion sites and hairpin structures. The plasmids pTZU6+1, pAdTrack, pAdEasy-1 and the E. coli BJ5183, JM109, DH5α strains were preserved in our lab. The HepG2, AD293, and SMMC-7721 cell lines were purchased from the IBCB, CAS.
Construction of pTZU6+1-siRNA-RhoA
The six oligodeoxyribonucleotides were annealed. The methods for constructing the pTZU6+1-siRNA-RhoA, extracting the recombinant plasmids and identifying the constructs were the same as those found in our previously published article [15] .
Cell culture conditions
AD293, HepG2 and SMMC-7721 cell lines were incubated in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) at 37℃, with 100U/mL penicillin and 100 U/mL streptomycin in a 5% CO 2 atmosphere. The cell growth state was observed periodically, and cells in the exponential phase were digested with a 0.25% trypsin solution containing 0.02% EDTA.
In vitro transfection
To plasmids, HepG2 cells were transfected respectively with 4 μg of pTZU6+1, psiRNA-RhoA-1, psiRNA-RhoA-2, or psiRNA-RhoA-3 according to our previous study [15] . To adenovirus, HepG2 cells were infected with the recombinant adenovirus suspension for 72 h with the titer of 2.0 × 10 8 pfu/mL. The infection rates were measured according to the fluorescence expression. The lysate protein concentrations were detected with a BCA kit (Boster, No. AR0146) according to the manufacturer's instructions.
Construction of adenovirus-mediated RhoA siRNA
The RhoA siRNA fragment was first inserted into the Kpn I and Hind III site of the shuttle vector pAdTrack, and then, it was transfected into AD293 cells by lipofection to generate recombinant adenovirus pAdTrack-RhoA. After linearization with Pme I, the pAdTrack-RhoA was co-transfected with the adenovirus frame vector pAdEasy TM -1 into E. coli BJ5183 to generate the recombinant plasmid pAdshRNA-RhoA. This plasmid was linearized again with Pac І and then transfected into the adenovirus package AD293 cell line for 1-2 weeks for virus formation. Subsequently, the virus, which was named AdshRNA-RhoA, was observed by GFP expression and harvested by freeze-thawing and centrifuging the cells. The recombinant virus purification, amplification, and titer determination were all conducted in a manner similar to that of our previous study [16] . The recombinant virus AdU6-control was constructed using the same method, but a siRNA fragment was not inserted.
Western blot and RT-PCR analysis
The processes were similar to that in our previously published article [15] .
MTT assays
The infected HepG2 cells were cultured in 96-well plates (103-104 cell/well) in 200 μL/well medium at 37℃ in a 5% CO 2 atmosphere for 72 h. TNF-α was added into the experimental group at a concentration of 1 μg/mL, and the cells were incubated for 48 h. MTT liquor (50 μL/well) was added to all of the wells, and the cells were continuously incubated for 3 h. Afterwards, the reaction buffer was replaced by a DMSO solution (150 μL/well), and the plate was placed on the microwell plate oscillator for 10 min. The results were measured by an enzyme-labeled instrument at 570 nm.
TdT-mediated UTP end labeling (TUNEL) assays
HepG2 cells were infected with AdshRNA-RhoA and AdshRNA-RhoA combined with TNF-α, respectively. The infected cells were grown for 72 h on coverslips, TUNEL analysis was performed according to the in situ Cell Death Detection kit instruction (Roche Molecular Biochemicals, Switzerland). Any apoptotic strand breaks were revealed by fluorescence and were photographed with a Photometrics Cool Snap ES. Cells infected with Ad-U6-control served as the blank control.
Flow cytometric analysis (FCA)
HepG2 cells were seeded at a density of 1 × 10 6 cells/well into 6-well plates in a process that is similar to that in our previously published article [16] .
Statistical analysis
The results were analyzed using SPSS18.0 software, and difference between two groups was compared using a student test. P-values less than 0.05 were considered to be significant.
Results
Construction of pAdshRNA-RhoA
The three pairs of RhoA siRNAs were synthesized, annealed, and constructed into the pTZU6+1 vector, respectively. Successful constructions were confirmed by double digestion and sequencing (data not shown). The RhoA protein expression levels were measured by immunoblot, and the normalized RhoA protein levels of HepG2 cells transfected with pTZU6+1, psiRNA-RhoA-1, psiRNA-RhoA-2, and psiRNA-RhoA-3 were 90.25%, 29.36%, 19.26%, and 45.37%, respectively, as compared with that of HepG2 cells transfected with Lipofectamine (100.0%) (Figuer 1A). The results indicate that psiRNA-RhoA2 has the highest inhibition efficiency on the RhoA expression of HepG2 cells, and there was no significant difference between psiRNA-RhoA1 and psiRNA-RhoA2 (p > 0.05); however, the inhibition effect of psiRNA-RhoA3 was unsatisfactory and was significantly weaker than either psiRNA-RhoA1 or psiRNA-RhoA2 (p < 0.01). Then, the effects of both psiRNA-RhoA1 and psiRNA-RhoA2 on RhoA mRNA expression were detected by semiquantitative RT-PCR, and the normalized RhoA mRNA levels of HepG2 cells transfected with pTZU6+1, psiRNA-RhoA-1, and psiRNA-RhoA-2 were 90.25%, 20.37%, and 21.18%, respectively ( Figure 1B ). These results further confirm that both psiRNA-RhoA1 and psiRNA-RhoA2 can effectively inhibit RhoA expression, and again, there was not a significant difference between them (p > 0.05). Thus, siRNA-2 was selected as the candidate for adenovirus-mediated siRNA construction.
The pAdshRNA-RhoA construct was generated using the recombinant psiRNA-RhoA-2 and the adenovirus shuttle vector pAdTrack ( Figure 1C ). Successful construction was identified by restriction digest analysis ( Figure 1D ) and was confirmed by sequencing. The digested products of pAdTrackRhoA were 50 bp larger than the control group located in lane 4, thereby indicating that the U6+1 promoter and the siRNA inverted repeat sequence fragment were successfully cloned into the vector pAdTrack. The PmeI-linearized positive pAdTrack-RhoA and pAdEasy-1 were co-transfected into E. coli BJ5183 to generate the recombinant pAdshRNA-RhoA. Digestion with PacI yielded a 4.5-kb or 3.0-kb DNA fragment and confirmed the positive recombinant in lanes 3-5 ( Figure 1E ). The control plasmid pAdU6-control was constructed in the same manner as pAdshRNA-RhoA, except only the U6+1 promoter was cloned into pAdU6-control. 
Generation of recombinant adenovirus AdshRNA-RhoA
Since the AD293 cell line allows for the production of infectious virus particles when cells are transfected with E1-deleted adenovirus vectors [17] (such as pAdEasy™-1 vector), it was used to propagate adenoviral recombinants in this study. The adenoviral recombinants pAdshRNA-RhoA and pAdU6-control were each digested with PacI and then transfected into HepG2 cells. The original virus suspensions were harvested when the infected cells appeared to float and exhibited visible virus spots after 7-12 days. Next, larger numbers of HepG2 cells were infected with the original virus suspensions in order to generate more adenovirus. The virus was collected according to the GFP expression observed by fluorescence microscopy (Figures 2A and 2B) . The titer of the recombinant virus was as follows: AdshRNA-RhoA, 2.1×10 8 pfu/mL and AdU6-control, 1.8×10 8 pfu/mL. After cesium chloride gradient centrifugation, the final titer was 2.4×10 9 pfu/mL for AdshRNA-RhoA and 2.1×10 9 pfu/mL for AdU6-control. Accordingly, the levels of the GAPDH internal control remained unchanged ( Figure 3A) . Next, western blot analysis was performed to analyze the RhoA protein expression levels after adenoviral infection. The results were similar to the RT-PCR results. More specifically, the AdshRNA-RhoA-infected cells showed significantly reduced levels of RhoA protein expression (23.52%) than in either the control cells or the AdU6-control-infected cells (98.20%) (p < 0.01). Moreover, there was not a significant difference between the RhoA levels in uninfected cells and those of AdU6-control-infected cells (p > 0.05). Again, the GAPDH expression was unchanged ( Figure 3B ). These results indicate that the recombinant adenovirus AdshRNA-RhoA efficiently inhibited RhoA expression at both the mRNA and protein levels.
Inhibition of HepG2 cell proliferation by TNF-α was augmented with AdshRNA-RhoA
Because the proliferation activity of a tumor cell is important for its metastasis and invasion ability, an MTT assay was used to evaluate HepG2 cell proliferation activity. The negative control group was infected with the AdshRNA-U6 adenovirus to eliminate any possible interference from the adenovirus-mediated siRNA expression system. The HepG2 cells were divided into three groups and were treated as follows (see Table 1 ): TNF-α, AdshRNA-RhoA, and TNF-α+AdshRNA-RhoA. Surprisingly, the cells that were solely infected with AdsiRNA-RhoA showed no significant difference in cell survival rate as compared to AdU6-control-infected cells (p > 0.01), thus indicating that the inhibition of RhoA expression did not directly impact the HepG2 cell proliferation activity. In contrast, a considerably low survival rate of HepG2 cells (47.5%) was observed in the TNF-α alone treatment group, which demonstrates that TNF-α is an efficient candidate for developing therapeutic treatments for HCC. Moreover, when TNF-α-treated HepG2 cells were simultaneously infected with AdshRNA-RhoA, the suppression rate of HepG2 cells increased markedly (p < 0.001) as compared to the cells treated by TNF-α alone. For example, the recombinant AdshRNA-RhoA adenovirus improved the suppression effect of TNF-α from 52.5% to 66.7% (p < 0.01), demonstrating that adenovirus-mediated RhoA siRNA can effectively augment TNF-α's effect on the inhibition of HepG2 cell proliferation in vitro.
AdshRNA-RhoA enhanced the apoptosis of HepG2 cells induced by TNF-α
Because the ability to induce tumor cell apoptosis is a necessary requirement of antitumor drug design and application, TUNEL and FCA analyses were performed to assess the potential antineoplastic effect of both AdshRNA-RhoA alone and the combined AdshRNA-RhoA + TNF-α. Cells infected with Ad-U6-control were used as the experimental control in order to confirm any and low TNF-α doses are capable of inducing HepG2 cell apoptosis but only to a certain low extent. However, the combined treatment significantly increased the number of apoptotic cells, which indicates that the specific inhibition of RhoA expression by adenovirus-mediated siRNA can enhance the spontaneous apoptosis of HepG2 cells induced by TNF-α.
Discussion and conclusion
Several studies have demonstrated that the inhibition of target genes that are highly expressed in tumor cells is a useful therapeutic route in HCC [18] , especially when targeting genes relevant to the combination of unrestrained cell proliferation and impaired apoptosis [19] . Furthermore, RNA interference has been widely used in the anti-tumor field; however, the traditional method of employing siRNA vectors is highly limited. In particular, the transfection efficiency is not stable, and applying the technology to animal model systems is difficult to accomplish [16, 20] .
In this study, when HepG2 cells were infected with a recombinant virus for 36 h, approximately 90% of the HepG2 cells displayed GFP expression under fluorescence microscopy, which indicates that the adenovirus had high transduction efficiency in the target tumor cells. It was also found that the infection efficiency is correlated to the cell source. The transfection efficiency of the recombinant virus was evaluated by the MOI (multiplicity of infection) value. The 100% infection rate of the AdshRNA-RhoA and AdU6-control virus to the HepG2 cell line required the MOI to reach about 20, which is the same value that was necessary for the other human hepatoma cell line SMMC-7721. However, in the human embryonic kidney cell line AD293, the MOI value was 10. Thus, the cell source from different tissues likely plays an important role in regulating the recombinant adenovirus transfection efficiency, and we believe that further research on this point will be highly beneficial for the rational application of recombinant adenovirus. Furthermore, the application of such a stable adenovirus vector system is convenient and does not produce any adverse effects on animal models [21] . Thus, this system can be easily used in animal experiments to test gene therapeutic effects, as was shown in our previously published article [20] . Many studies have previously established that the Rho GTPases/Rho-effector pathway plays important roles in mediating HCC metastasis, based on its foremost function of orchestrating the cytoskeletal reorganization in the cell [22] . For example, Wong et al. successfully suppressed the proliferation and invasion of HCC cells by deleting the Rho GTPase-activation protein in the liver [23] . As a member of the Rho GTPase family, RhoA is an important factor in promoting the uncontrolled proliferation as well as the invasive and metastatic properties of cancer cells [24] . Accordingly, the clinicopathological correlation of RhoA levels with HCC has been widely evaluated, and it was found that a high RhoA protein expression is detectable in both idiopathic and early-stage recurrent HCC [9] , and high expression is also closely related to venous invasion, differentiation [11] , tumor progression, and the metastasis of hepatocarcinoma cells [25, 26] . Moreover, proteomic analysis also identified RhoA as one of the most significantly up-regulated proteins in HCC [27] . Thus, RhoA was selected as a good target for HCC therapy.
Recently, biological approaches for inhibiting RhoA expression in order to induce tumor cell apoptosis have been tested with relative success [28, 29] . One report demonstrated that the suppression of RhoA expression in HepG2 and Hep3B cells by RNA interference led to cell growth inhibition, apoptosis, and a decrease in migration [27] . However, our results showed that AdshRNA-RhoA produces no apparent effect on either suppressing proliferation or inducing the apoptosis of infected HepG2 cells, despite its confirmed effect in silencing RhoA expression. These results also contrasted with results from our similar investigation in the breast cancer cell line T47D. Moreover, we also tested the suppression effect of AdshRNA-RhoA in this cancer cell line and found that the AdshRNARhoA exhibits intensive inhibition activity on T47D cell proliferation and induced a large portion of cell apoptosis (data not shown). The mechanism of this apparent discrepancy remains unclear; however, a new report on miR-21 [30] may provide some assistance in elucidating this inconsistency. In this new report, it was demonstrated that the suppression of miR-21 by the newly discovered regulator indole-3-carbinol (I3C) could repress the PTEN/AKT (phosphatase and tensin homolog/protein kinase B) pathway, leading to an inhibition of tumorigenesis in the hepatocarcinomal cell. Moreover, activation of RhoA by the downstream effector Rock (RhoA-associated kinase) can stimulate the phospholipid phosphatase activity of PTEN in human embryonic kidney cells and leukocytes [31] , and in turn, the activated PTEN down-regulates AKT activity, which is essential for cell proliferation [32] . Furthermore, F. Fusella, et al. [33] also reported that PTEN destabilization caused by the high morgana levels in breast cancer cells triggered the PI3K/AKT survival pathway; thus, the cells' self-protective activity from various apoptotic stimuli was strongly enhanced. Differences in the apoptotic rates among different cancer cell lines caused by RhoA inhibition may be correlated with the RhoA-ROCK-PTEN pathway, but the mechanism needs to be further investigated. We also speculate that RhoA may need an enhancer or cooperator, such as TNF-α, for achieving its maximal function on suppressing hepatocarcinoma cell proliferation and inducing apoptosis.
It has been widely established that TNF-α can enhance the function of anti-tumor drugs, and the RhoA/Rho signaling pathway and RhoA activity can both be influenced by TNF-α in diverse cell lines. Furthermore, TNF-α can induce the activation of the ERK/GEF-H1/RhoA pathway in tubular cells, which is mediated through Src-and TACE-dependent EGFR activation [2] . The RhoA mRNA expression in human bronchial smooth muscle can also be induced by cytokines, such as IL-13 and TNF-α, and additionally, STAT6 and NF-κB are important for this up-regulation [34] . TNF-α can also induce the up-regulation of RhoA via NF-κB activation in cultured human bronchial smooth muscle cells [35] . This up-regulation mechanism of RhoA was mediated by GEFF-H1, as the siRNA-induced down-regulation of GEFF-H1 prevented the activation of the Rho pathway [36] . However, the precise candidates involved in the TNF-α and RhoA correlation in tumorigenesis remain elusive. Furthermore, it is important to note that, although it has been widely established that TNF-α can enhance the function of anti-tumor drugs, in this study, it appeared that AdshRNA-RhoA rather than TNF-α played the auxiliary role. These results have demonstrated that the down-regulation of RhoA together with TNF-α can significantly induce HepG2 cell apoptosis, which suggests that the suppression of RhoA can improve the auxiliary curative effect of TNF-α on both cell proliferation and apoptosis. The molecular mechanisms underlying these effects are still unclear and need to be further investigated.
In conclusion, the combined RhoA adenovirus-mediated siRNA with low doses of TNF-α in HepG2 cells significantly affects cell apoptosis, as well as affects the inhibition of cell proliferation. This is the first study to use an anti-tumor cytokine and Rho GTPase siRNA together to induce tumor cell apoptosis, and the data we have produced suggest promising applications in the HCC gene therapy field. As both RhoA and TNF-α are relevant in metastasis [1, 26, 37] , this data may also be applied to the inhibitions of other types of tumor cells.
